-
-
-
-
-
-
-
UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
-
-
-
-
-
-
-
Kalaris Therapeutics (KLRS) Closes Merger with AlloVir
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

